Insulin Copay Sham

John explains how the proposed $35 copay on insulin analogs is a sham designed to protect brand name manufacturers and prevent competition from biosimilar products. He also discusses how the current political climate makes it unlikely for reasonable regulations to be put in place to address these issues.